Evidence map›Paper›PMID 41674227›Full record

ReviewEndocrinology and metabolism (Seoul, Korea)2026

Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.

Thanh T Nguyen, Tam Dao, Ha Thu Nguyen, Jun-Hyeon Park, Seung-Jun Jeong, Sei Kim, Yunju Jo, Nhung T H Thieu, Jiangqi Zhao, Fuan Ding and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology and metabolism (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thanh T NguyenDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Tam DaoDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Ha Thu NguyenDepartment of Hematology, Vietnam National Children's Hospital, Hanoi, Vietnam.
Jun-Hyeon ParkDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Seung-Jun JeongDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Sei KimDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Yunju JoDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Nhung T H ThieuDepartment of Pediatrics, Hong Ngoc Phuc Truong Minh General Hospital, Hanoi, Vietnam.
Jiangqi ZhaoDivision of Dermatology, The Second Hospital of Jilin University, Changchun, China.
Fuan DingDivision of Vascular Disease, The Second Hospital of Jilin University, Changchun, China.
Ying YuDivision of Orthopedics, Changchun University of Chinese Medicine, Changchun, China.
Vu Chi DungCenter of Endocrinology, Metabolism, Genetic/Genomics and Molecular Therapy, Vietnam National Children's Hospital, Hanoi, Vietnam.
Karim GarianiDivision of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medical Specialties, Geneva University Hospital, Geneva, Switzerland.
Beom-Jun KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. umkbj0825@amc.seoul.kr.
Dongryeol RyuDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea. dryu@gist.ac.kr.

Funding

Korea Health Industry Development InstituteMinistry of Education RS-2024-00401934Ministry of Health and WelfareMinistry of Science and ICTNational Research Foundation of Korea RS-2023-NR077276
6 · The paper itself

Abstract

Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function, which increases the risk of falls, frailty, and loss of independence. Despite growing recognition and its incorporation into geriatric assessments, there is still no approved pharmacological treatment. This review provides an updated overview of sarcopenia, encompassing diagnostic criteria, biological mechanisms, and emerging therapeutic strategies. Key molecular features include mitochondrial dysfunction, nicotinamide adenine dinucleotide (NAD⁺) decline, fiber-type alterations, and dysregulation of myokines. Recent singlecell and multi-omics studies have revealed the heterogeneity of muscle tissue and distinct cell-type-specific aging patterns. Therapeutic efforts are evolving beyond lifestyle interventions toward targeted approaches, including myostatin inhibitors, NAD⁺ boosters, senolytics, and microbiome modulators. However, clinical translation remains constrained by heterogeneity in trial design and the absence of standardized outcome measures. Future sarcopenia care will likely involve precision medicine guided by biomarkers and supported by digital monitoring tools. Progressing from molecular discovery to clinical application will be essential for preserving muscle health and function in aging populations.

Indexed as

AgingMuscle, SkeletalSarcopeniaAnimalsHumansMyokinesTranslational Research, BiomedicalMyokinesAgingMitochondriaMuscle weaknessMyokinesProtein metabolismSarcopeniaSkeletal muscle

Identifiers

PMID41674227
PMCPMC12963776

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.